Neurology Medical News about children with medulloblastoma;glutathione S-transferase M1 and T1 polymorphisms

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma
Neuro-Oncology, 06/12/09

Nadia Barahmani N et al. – A study of whether glutathione S-transferases (GSTs) polymorphisms are in part responsible for individual differences in toxicity and responses in pediatric medulloblastoma concludes that GSTM1 and GSTT1 polymorphisms may predict adverse events, including cognitive impairment after therapy, in pts with medulloblastoma.

Methods

Study of the relationship between GSTM1 and GSTT1 polymorphisms and survival and toxicity in 42 children with medulloblastoma
Kaplan-Meier analyses to determine if GST polymorphisms related to progression-free survival
Logistic regression to explore associations between GST polymorphisms and occurrence of ≥grade 3 (Gr 3) myelosuppression, ototoxicity, nephrotoxicity, neurotoxicity, and intellectual impairment.

Results

Pts with ≥1 null genotype had a 4.3, 3.7, and 6.4 times increased risk for any Gr 3 toxicity, any Gr 3 toxicity excluding peripheral neuropathy, and any Gr 3 toxicity requiring omission or cessation of chemotherapy, respectively
Pts with ≥1 null genotype had an average 27.2, 29, and 21.7 lower full-scale, performance, and verbal intelligence quotient scores, respectively

<< Previous
Evaluation of efficacy and safety of anterior corpus callosotomy...

Next >>
Chronic glucocorticoid hypersecretion in Cushing’s...